I-catching R&D

Like other pharma companies before it, AstraZeneca plc has concluded the best way to increase its innovative capacity is to create smaller near-autonomous disease area-focused units and make its own internal activities compete head-to-head with external opportunities for R&D funds. The new strategy unveiled at last week's annual results meeting adds another wrinkle:promising projects will need to demonstrate they are cost effective in the eyes of payers.

CEO David Brennan said the company achieved significant launches of Onglyza saxagliptin for Type II diabetes in

Read the full 839 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers